RDInvesting Provides Investors with Free In-Depth Equity Reports on AREX, BLMN, DLPH and SPPI
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Approach Resources Inc. (NASDAQ: AREX) shares declined 0.74 percent to close at $25.65 a share Tuesday. The stock traded between $25.24 and $25.95 on volume of 526,744 shares traded. Analysts at Miller Tabak have recently initiated coverage on the company with a “buy” rating and a price target of $30.00. Shares of Approach Resources have gained approximately 2.5 percent year-to-date.
Find out more about Approach Resources including full access to the free equity report at:
www.RDInvesting.com/AREX
Bloomin' Brands Inc. (NASDAQ: BLMN) shares gained 0.80 percent to close at $25.17 a share Tuesday. The stock traded between $24.22 and $25.45 on volume of 1.81 million shares traded. Analysts at JPMorgan have recently downgraded the company’s rating to “neutral” from “overweight”. Shares of Bloomin' Brands have gained over 60.0 percent year-to-date.
Find out more about Bloomin' Brands including full access to the free equity report at:
www.RDInvesting.com/BLMN
Delphi Automotive PLC (NYSE: DLPH) shares declined 1.82 percent to close at $54.00 a share Tuesday. The stock traded between $53.65 and $54.51 on volume of 2.27 million shares traded. Analysts at Goldman have recently downgraded the company’s rating to “neutral” from “buy”. Shares of Delphi Automotive have gained approximately 41.0 percent year-to-date.
Find out more about Delphi Automotive including full access to the free equity report at:
www.RDInvesting.com/DLPH
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) shares increased 2.18 percent to close at $8.89 a share Tuesday. The stock traded between $8.35 and $9.21 on volume of 2.86 million shares traded. Analysts at JMP Securities have recently upgraded the company’s rating to “market perform” and currently have a $12.00 price target on the stock. Shares of Spectrum Pharmaceuticals have fallen approximately 20.5 percent year-to-date.
Find out more about Spectrum Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/SPPI
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
info@rdinvesting.com